Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10476730 | 1.00 | BTK (0.50) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL3339805 | 1.00 | BTK (0.50) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL4083645 | 1.00 | BTK (0.50) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL1503739 | 1.00 | BTK (0.50) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL4362967 | 0.88 | BTK (0.64) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL4359099 | 0.88 | BTK (0.64) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL31664496 | 0.87 | BTK (0.47) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL5902017 | 0.87 | KMT2A (0.47) | BTKKDM1AMAOBKMT2AL3MBTL1 | |
| SCHEMBL1503772 | 0.84 | BTK (0.44) | BTKKDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL13672053 | 0.84 | BTK (0.44) | BTKKDM1AMAOBNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | BTK 13/4885KDM1A 3872/4885MAOB 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.